Literature DB >> 32898723

Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

Wei-Chih Chen1, Gangqing Hu2, Lori A Hazlehurst3.   

Abstract

The bone marrow microenvironment (BMM) provides input via production of cytokines, chemokines, extracellular matrixes in the context of lower oxygen levels that influences self-renewal, survival, differentiation, progression, and therapeutic resistance of multiple myeloma and leukemic cells. Within the context of the BMM, tumor cells are supported by osteoblasts, bone marrow stromal cells (BMSCs), fibroblasts, myeloid cells, endothelial cells and blood vessels, as well as extracellular matrix (ECM) that contribute to tumor progression. Environmental mediated-drug resistance (EM-DR) contains cell adhesion-mediated drug resistance (CAM-DR) and soluble factor-mediated drug resistance (SM-DR) that contributes to de novo drug resistance. In this review, we focus on the crosstalk between the BMM and tumor cells as well as mechanisms underlying the BMM contributing to drug resistance in hematologic malignancies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32898723      PMCID: PMC7770000          DOI: 10.1016/j.coph.2020.08.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  88 in total

1.  Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance.

Authors:  Mark J Kiel; Glenn L Radice; Sean J Morrison
Journal:  Cell Stem Cell       Date:  2007-08-16       Impact factor: 24.633

2.  Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

Authors:  Byung-Sik Cho; Zhihong Zeng; Hong Mu; Zhiqiang Wang; Sergej Konoplev; Teresa McQueen; Marina Protopopova; Jorge Cortes; Joseph R Marszalek; Sheng-Bin Peng; Wencai Ma; R Eric Davis; Donald E Thornton; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

Review 3.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model.

Authors:  Dian L Olson; Linda C Burkly; Diane R Leone; Brian M Dolinski; Roy R Lobb
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

5.  Knockdown of N-cadherin suppresses the long-term engraftment of hematopoietic stem cells.

Authors:  Kentaro Hosokawa; Fumio Arai; Hiroki Yoshihara; Hiroko Iwasaki; Yuka Nakamura; Yumiko Gomei; Toshio Suda
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

Review 6.  Integrin-mediated drug resistance in multiple myeloma.

Authors:  J S Damiano; W S Dalton
Journal:  Leuk Lymphoma       Date:  2000-06

7.  Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells.

Authors:  W-C Cheung; B Van Ness
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

8.  Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Authors:  Tomohiro Umezu; Hiroko Tadokoro; Kenko Azuma; Seiichiro Yoshizawa; Kazuma Ohyashiki; Junko H Ohyashiki
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

9.  Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prajwal Boddu; Gautam Borthakur; Mythili Koneru; Xuelin Huang; Kiran Naqvi; William Wierda; Prithviraj Bose; Elias Jabbour; Zeev Estrov; Jan Burger; Yesid Alvarado; April Deshmukh; Ami Patel; Antonio Cavazos; Lina Han; Jorge E Cortes; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Front Oncol       Date:  2018-09-24       Impact factor: 6.244

Review 10.  Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.

Authors:  Margot de Looff; Steven de Jong; Frank A E Kruyt
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

View more
  6 in total

1.  Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production.

Authors:  Christopher Uhl; Themba Nyirenda; David S Siegel; Woo Y Lee; Jenny Zilberberg
Journal:  Heliyon       Date:  2022-03-24

Review 2.  Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours.

Authors:  David Greaves; Yolanda Calle
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

3.  The expression of heat shock protein A12B (HSPA12B) in non-Hodgkin's lymphomas.

Authors:  Yuejiao Huang; Chunlei Peng; Jie Tang; Shitao Wang; Fan Yang; Qiufei Wang; Li Zhou; Lei Yang; Shaoqing Ju
Journal:  Ann Transl Med       Date:  2021-09

4.  Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma.

Authors:  Sebastian A Dziadowicz; Lei Wang; Halima Akhter; Drake Aesoph; Tulika Sharma; Donald A Adjeroh; Lori A Hazlehurst; Gangqing Hu
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

5.  A novel in vitro 3D model of the human bone marrow to bridge the gap between in vitro and in vivo genotoxicity testing.

Authors:  Alexander R Vernon; Roy M Pemberton; H Ruth Morse
Journal:  Mutagenesis       Date:  2022-05-04       Impact factor: 2.954

Review 6.  CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.

Authors:  Yuejiao Huang; Yuchan Wang; Jie Tang; Shiyi Qin; Xianjuan Shen; Song He; Shaoqing Ju
Journal:  Front Cell Dev Biol       Date:  2021-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.